1. General
  2. Others

  3. Others

Dr. Reddy’s Laboratories launches Olanzapine Tablets

India Infoline News Service | Mumbai | April 25, 2012 08:36 IST

The ZYPREXA Tablets brand and generic had combined U.S. sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.

Dr. Reddy’s Laboratories announced today that it has launched Olanzapine Tablets (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg), a bioequivalent generic version of ZYPREXA Tablets in the US market on April 23, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Olanzapine Tablets.

Dr. Reddy’s Olanzapine Tablets in 20 mg had been awarded a 180-day period of marketing exclusivity in the U.S. on October 26, 2011 which was commercialized through a commercial, manufacture and supply agreement with Teva Pharmaceutical Industries Ltd.

The ZYPREXA Tablets brand and generic had combined U.S. sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.

Dr. Reddy’s Olanzapine Tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths are available in 30 and 500 count bottles.

BSE 3,344.85 [16.60] ([0.49]%)
NSE 3,349.60 [11.65] ([0.35]%)

***Note: This is a BSE Chart


Read more on: Dr.  Reddy’s  Laboratories 
article
113103103819
Dr. Reddy’s Laboratories launches Olanzapine Tablets
Dr. Reddy’s Laboratories launches Olanzapine Tablets
The ZYPREXA Tablets brand and generic had combined U.S. sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.
http://www.indiainfoline.com/article/news-top-story/dr-reddy’s-laboratories-launches-olanzapine-tablets-113103103819_1.html
April 25, 2012 08:36 IST
http://content.indiainfoline.com/_media/iifl/img/article/old/full/1718993566_LS_drreddylab
Dr. Reddy’s Laboratories
Others
$rawVideoFileUrl$
$videoPlayerUrl$

 
 
Reports

Another day, another high

India Infoline News Service / 09:04, Jan 22, 2015

The outlook is a flat start. The market will look to scale to new peaks though not much effort is needed for the same. HUL saw a rally and short-covering may have pulled it up further. Speculation is on that its parent will raise stake through an open offer. After the cooling in oil prices, Cairn results will be in focus.

News